Tag Archive for: oncology

Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory Board and Significant Public Grant Funding

Cycuria aims to revolutionise treatment of hard-to-treat blood cancers with a first-in-class protein-based therapeutic approach specifically targeting both tumour cells and tumour stem cells Advisory Board unites distinguished experts in corporate strategy, clinical haemato-oncology, protein engineering and early-stage drug discovery and development Grant funding secured from innovation-supporting Austrian government bodies FFG and AWS Graz, Austria, […]

Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer

Revolutionary ‘off-the-shelf’ cancer vaccine designed to prevent the recurrence of oesophageal cancer ITOP1 to enter first-in-human Phase I/IIa clinical development in the VISTA study in H1 2025 Multicentre study to be conducted at four university cancer centres, aiming to raise the standard of care by reducing the recurrence of metastases and cancer-related deaths Oxford, UK […]

Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025

Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters present the potential of GPCRs to modulate the tumor microenvironment and enhance anti-tumor immunity Strasbourg, France – Montreal, […]

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer

Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalities AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses Lund, Sweden, […]

Ottimo Pharma Strengthens Leadership Team with Senior Appointments

Robert Tighe appointed as Senior Vice President of Preclinical and Translational Sciences and Katherine Bell-McGuinn, M.D., Ph.D. appointed as Senior Vice President of Clinical Development  Appointments support Ottimo Pharma as it rapidly advances the clinical development of lead candidate, Jankistomig, its first-in-class dual pathway, biparatopic IgG1 therapy  IND clearance for Jankistomig is on track for […]